Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock analysis
Want to see HK:1276 full AI Analyst Report?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Stock Price & Analysis
1276 Stock Chart & Stats
- Day’s Range
- HKD 49.06 - HKD 50.75
- 52-Week Range
- HKD 43.02 - HKD 80.95
- Previous Close
- HKD 50.25
- Volume
- N/A
- Average Volume (3M)
- 4.38M
- Market Cap
- HKD 372.50B
- Enterprise Value
- HKD 281.48B
- Total Cash (Recent Filing)
- HKD 50.97B
- Total Debt (Recent Filing)
- HKD 493.42M
- Price to Earnings (P/E)
- 35.5
- Beta
- 0.49
- Next Earnings
- Apr 19, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Apr 29, 2026
- Dividend Yield
- 0.46%
Bulls Say, Bears Say
Bulls Say
High Profitability
Exceptional gross and net margins indicate strong economics across the company’s pharmaceutical portfolio. This profitability provides resources for research, clinical development, commercialization, and market expansion while offering resilience against moderate cost or pricing pressure over the next several quarters.
Conservative Balance Sheet
Extremely low leverage gives Hengrui substantial financial flexibility and minimizes refinancing risk. A stronger equity and asset base can support continued investment in drug development and commercialization without relying heavily on debt, improving durability through changing industry conditions.
Strong Cash Generation
Strong operating cash flow that exceeds reported earnings demonstrates meaningful cash support for the business model. This internally generated funding can sustain research investment, production, and commercialization while reducing dependence on external financing for ongoing growth.
Bears Say
Volatile Free-Cash-Flow Conversion
Although operating cash generation is strong, free-cash-flow conversion has been uneven and was negative in 2022. Periodic working-capital swings or investment cycles can make cash available for reinvestment less predictable than accounting earnings over the medium term.
Margin Pressure
Recent margin softening suggests that product mix, pricing, or spending may be weighing on operating profitability. If this persists, it could reduce the earnings benefit of revenue growth and limit the amount of cash available for research, commercialization, and other strategic investments.
Uneven Revenue Growth
The recovery in revenue is encouraging, but the sharp 2022 decline and slower TTM growth show that expansion has not been consistently smooth. Uneven top-line performance can complicate capacity planning and make future earnings growth more dependent on successful product and market execution.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H News
Hengrui Pharma Seals Up to US$2.6 Billion Global Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Drug
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) has issued an update. Jiangsu Hengrui Pharmaceuticals has signed a license agreement with Novo Nordisk A/S for HRS-1596, its independently
Hengrui Pharma Clears All Resolutions at 2026 Extraordinary Shareholders’ Meeting
An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) is now available. Jiangsu Hengrui Pharmaceuticals reported that all resolutions at its first extraordinary shareholders’ meeting of
Hengrui Wins NMPA Approval for New Uses of Innovative Thrombocytopenia Drug
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) has shared an update. Jiangsu Hengrui Pharmaceuticals has received approval from China’s National Medical Products Administration for two new indications
Hengrui Pharmaceuticals Calls Extraordinary Meeting on New Share Schemes and Buyback Mandate
An announcement from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) is now available. Jiangsu Hengrui Pharmaceuticals has called a first extraordinary shareholders’ meeting for September 24, 2026
1276 FAQ
What was Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap?
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
How were Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H overvalued?
Does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pay dividends?
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
How many shares outstanding does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H have?
What happened to Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Company Description
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sun Piaoyang
- Employees
- 20,602
- Website
- www.hengrui.com
- Address
- No. 38, Huanghe Road, Lianyungang, JS, 222047, CN
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Earnings & Revenues
1276 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 10 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 4 | 0 | 8 |
